Quantcast

Latest Palonosetron Stories

2011-06-08 05:00:00

LONDON, June 8, 2011 /PRNewswire/ -- - New data presented at the European Hematology Association (EHA) 2011 Annual Meeting in London show better control of nausea and vomiting with the combination palonosetron plus aprepitant when compared to granisetron in patients receiving multiday highly emetogenic conditioning chemotherapy regimens - Significantly higher the complete response during the acute, delayed and overall periods The combination of palonosetron (0.25 mg iv every 48...

2010-08-12 00:30:00

NANJING, China, Aug. 12 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that its subsidiary company Simcere Dongyuan Pharmaceutical Co., Ltd. has recently received SFDA new drug certification and registration approval to manufacture and market Palonosetron material and...

2009-09-09 03:20:00

LUGANO, Switzerland, September 9 /PRNewswire/ -- As part of the Helsinn Group's development strategy, William Mann, PhD, has been appointed as new CEO in the American subsidiary, Helsinn Therapeutics (U.S.) Inc. William Mann, PhD, was already Chief Operating Officer of the recently acquired Helsinn Therapeutics, and has held leadership positions in a Swiss multinational with positions in Business Development and in Research. Moreover, Helsinn announces that Mr. William Brown has been...

2009-03-20 06:00:00

ZURICH, Switzerland, March 20 /PRNewswire/ -- A new, innovative study shows that a single dose of palonosetron, the second generation 5-HT3 antagonist, plus dexamethasone not only prevents chemotherapy-induced nausea and vomiting (CINV), but also allows adequate caloric intake in oncology patients. Data presented today at the ESMO Symposium on Cancer and Nutrition in Zurich, Switzerland New data presented today at the ESMO (European Society of Medical Oncology) Symposium on Cancer...

2008-12-04 07:00:00

WALTHAM, Mass., Dec. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Eisai/Helsinn Healthcare's Aloxi's marketing message ("Better in acute, better in delayed") is rated the most influential by oncologists in the chemotherapy-induced nausea and vomiting drug market. Oncologists accurately identified Aloxi's messages with the brand, highlighting the strength of the Aloxi messaging...

2008-11-05 06:00:06

A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2008. The company also announced additional positive clinical data for its lead product, APF530, which has successfully completed a Phase 3 trial for the treatment of chemotherapy-induced nausea and vomiting (CINV). In addition, in order to better focus the company's resources on APF530 in light of current conditions in the capital markets, A.P....


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin